It acts as an antagonist of GPR55, reducing the frequency, severity, and duration of spontaneous seizures, which has been demonstrated and validated in a genetic mouse model of Dravet syndrome [89]. Here, GPR55 is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.